Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic kidney disease stage V;~* on peritoneal dialysis for 3 months prior to screening;~* on epoetin alfa sc \>=3 months prior to screening.~Exclusion Criteria:~* patients expecting to change dialysis modality over course of study;~* patients hospitalized during previous 3 months for any clinically significant condition;~* active malignancy;~* bleeding episode necessitating transfusion, or overt gastrointestinal bleeding within 3 months prior to screening;~* transfusion of red blood cells within 3 months prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RO0503821 (Type: EXPERIMENTAL): Eligible participants will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta \[Mircera\]) subcutaneously (SC) every month for eight months (6 months of titration period \[TP\] and two months of evaluation period \[EP\] and 15-days following the final study visit (9 months post randomization). The first dose of Mircera (120, 200, or 360 mcg) will be based upon the dose of epoetin alfa received 1 to 2 weeks prior to administration of study drug, while subsequent doses will be adjusted to maintain haemoglobin (Hb) concentrations within target of \>=10.0 gram per decilitre (g/dL) and \<=12.0 g/dL. Participants who self-administered/visited to clinics for erythropoiesis stimulating agent (ESA) dosing prior to randomization will continue to do so.
- Epoetin Alfa (Type: ACTIVE_COMPARATOR): Eligible participants will be administered epoetin alfa SC as per the standard of care for eight months (TP and EP), and will be followed-up for 15 days following the final study visit. Participants who self-administered/visited to clinics for ESA dosing prior to randomization will continue to do so.

Based on this trial design, predict the completion outcome and termination type (if applicable).